Koi Biotherapeutics Inc.
PrivateLast Round
Accelerator
Oct 1, 2024
Company Overview
Koi Biotherapeutics Inc. is a biotechnology company that has developed a CAR-enhancer platform to improve the persistence and efficacy of CAR T-cell therapy for blood cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Koi Biotherapeutics Inc. Comps
Public and private peers based on sector, stage, and business model.
Koi Biotherapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Oct 1, 2024 | ||||
| Accelerator | Mar 18, 2024 |
Koi Biotherapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Endless Frontier Labs | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2024
Received funding from Endless Frontier Labs.
- Mar 18, 2024
Funding round included Bristol Myers Squibb and MassBio.
Koi Biotherapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Koi Biotherapeutics Inc.'s valuation, stock price, and market status.